Expand ALNY Menu
ALNY MENU

ALNY Latest Press Releases

-- May 12, 2026 --

New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden Business Wire 2:30 AM

-- May 7, 2026 --

Alnylam to Webcast Presentations at Upcoming Investor Conferences Business Wire 8:00 AM

-- May 4, 2026 --

Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM Business Wire 8:30 AM

-- April 30, 2026 --

Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress Business Wire 8:00 AM

-- April 20, 2026 --

When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech Globe Newswire 8:30 AM

-- April 16, 2026 --

Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results Business Wire 8:00 AM

-- March 30, 2026 --

New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management Business Wire 1:00 PM

-- March 24, 2026 --

Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association Business Wire 7:30 AM

-- March 10, 2026 --

Alnylam to Webcast TTR Investor Webinar Business Wire 8:00 AM

-- March 5, 2026 --

Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics Globe Newswire 8:30 AM

-- February 23, 2026 --

Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference Business Wire 10:00 AM

-- February 19, 2026 --

Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development Globe Newswire 8:30 AM

-- February 12, 2026 --

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress Business Wire 8:00 AM

-- January 29, 2026 --

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results Business Wire 8:00 AM

-- January 11, 2026 --

Alnylam Launches "Alnylam 2030" Strategy to Drive Next Era of Growth and Patient Impact Business Wire 5:00 PM

-- January 5, 2026 --

Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference Business Wire 9:15 AM

-- December 17, 2025 --

Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics Business Wire 8:00 AM

-- December 12, 2025 --

Annual Changes to the Nasdaq-100 Index Globe Newswire 8:00 PM
Market Data Delayed 15 Minutes